AOLS.ob

[kslifka]

AOLS.ob put in a G-pattern today.  This small biotech company has had some news as of late hence the activity in the stock.

I really like these dead stocks that come to life.

tudy Demonstrating Aeolus Compound's Neuroprotection in Parkinson's Disease Published in the Journal of Neuroscience
Thursday April 26, 10:00 am ET
AEOL 11207, Administered Orally, Crossed the Blood-Brain Barrier
First Demonstration of Neuroprotection by an Oral Catalytic Antioxidant in the MPTP (Parkinson's) Mouse Model

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS - News) announced today the publication* in the April 18, 2007 issue of the Journal of Neuroscience a study by researchers at the University of Colorado and National Jewish Medical and Research Center demonstrating that the Company's first orally available catalytic antioxidant, AEOL 11207, demonstrated neuroprotection in an animal model of Parkinson's disease ("PD"). The study also showed that the compound has favorable blood-brain barrier permeability.

ADVERTISEMENT
AEOL 11207 was tested for neuroprotection and oral bio-availability in the mouse MPTP model of Parkinson's disease. AEOL 11207 administered orally protected against MPTP-induced dopamine depletion in the striatum as well as dopaminergic neuronal loss, glutathione depletion, lipid peroxidation, and 3-nitrotyrosine formation in the ventral midbrain. Neuroprotection correlated with brain metalloporphyrin concentrations. The researchers concluded that AEOL 11207 demonstrated neuroprotection in the MPTP mouse model and that the data support further investigation of AEOL 11207 as a potential treatment for PD and other neuro-degenerative diseases.

The Potential for AEOL 11207 in Parkinson's and other Neurodegenerative Diseases

A major hurdle to the treatment of chronic neurodegenerative diseases is the development of efficacious and bioavailable therapeutic agents that permeate the blood-brain barrier. Catalytic removal of reactive species is a highly warranted, yet novel approach for the treatment of age related neurodegenerative diseases such as PD. The major therapeutic approach currently used to alleviate the symptoms of PD involves restoration of dopaminergic neurotransmission using levodopa, dopamine agonists, and inhibitors of monoamine metabolism. However, these therapeutic approaches are often associated with serious adverse effects and fail to provide long-term control of this inexorably progressive disease. Therefore, there is an urgent need for novel classes of therapeutic agents for the treatment of PD. This study provides evidence that a novel lipophilic metalloporphyrin penetrates the BBB following oral administration possesses a long plasma and brain half-life and provides significant neuroprotection by an antioxidant mechanism in a well-established animal model of parkinsonism. This is the first demonstration of protection by an orally active metal-based catalytic antioxidant in the MPTP model.

[422fwhp]

Nibbled a little today...dyodd

cant post chart...

[422fwhp]

here's a chart....